CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy Vertebral Fracture Assessment

Defines coverage position for vertebral fracture assessment (VFA) imaging, specifically VFA performed with dual-energy X-ray absorptiometry (DXA/DEXA) and VFA performed without bone density study; addresses Medicare Advantage and commercial product stances and reimbursement (separate payment) implications.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy Vertebral Fracture Assessment

Policy CodePolicy N/A

Change TypeClarified (no material changes)

Effective DateOct 1, 2015

Next Review Date

Key ActionVerify member-specific benefits and expect CPT 77086 to be covered but not separately reimbursed for Medicare Advantage and not medically necessary for Commercial members.

SourceLink

POLICY UPDATE CHANGES

Policy last updated 11/01/2023; no clinical policy statement changes indicated in document.

1CPT code listed

MedAdv: covered not reimbursed; Commercial: not necessaryCoverage summary

0Material change

Coverage Summary

This policy takes a mixed coverage stance for vertebral fracture assessment (VFA) by dual-energy X-ray absorptiometry (DXA). For Medicare Advantage plans VFA (CPT 77086) is covered but not separately reimbursed. For Commercial Products, VFA performed as screening without a bone density study is considered not medically necessary because the evidence is insufficient to determine effects on health outcomes. The policy scope addresses VFA performed with DXA and VFA performed without a bone density study and notes implications for separate payment and benefit verification.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Policy Statements & Medical Necessity

Policy Statement - Coverage and Medical Necessity

Coverage and medical necessity statements as provided in the policy:

Policy Statement

Medicare Advantage: Screening for vertebral fractures with dual-energy X-ray absorptiometry (DXA or DEXA), without bone density study, is covered but not separately reimbursed.
Applies to Medicare Advantage Plans.
Commercial Products: Screening for vertebral fractures with dual-energy X-ray absorptiometry (DXA or DEXA), without bone density study, is considered not medically necessary due to insufficient evidence of benefit.
Commercial products: not medically necessary; no separate reimbursement.

ref": "b1_0", "title": "Policy Statement - Coverage and Medical Necessity"

title": "Policy Statement - Coverage and Medical Necessity"}

ERROR_PLACEHOLDER

Prior Authorization

Prior authorization requirements:

Prior Authorization: Prior authorization: Not applicable.

Medical Criteria

Medical necessity criteria:

Medical Criteria: Medical criteria: Not applicable.

Provider Actions & Billing Guidance

Billing Rule

Separate reimbursement restriction for 77086

CPT code 77086 (vertebral fracture assessment via DXA) is covered for Medicare Advantage Plans but is not separately reimbursed. For Commercial Products, 77086 is considered not medically necessary. Providers should not expect separate payment for 77086 under Medicare Advantage and may face claim denials for Commercial members.

Affected code(s): 77086
Medicare Advantage: covered but not separately reimbursed (no separate payment expected).
Commercial Products: not medically necessary (may result in denial).

Documentation Required

Benefit verification

Benefits and coverage may vary by group and contract. Providers must refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement and verify member-specific benefits (or call the provider call center) prior to providing services.

Verify member-specific benefits in the Benefit Booklet/Evidence of Coverage/Subscriber Agreement.

Background and Evidence Summary

Vertebral fracture assessment (VFA) performed with DXA is a low-radiation technique that uses specialized densitometer software to image the lateral spine at the time of bone mineral density testing. VFA detects vertebral fractures (commonly graded using the Genant semiquantitative method) but, unlike conventional lateral spine radiographs, can only detect fractures and does not detect other bone or soft-tissue abnormalities. The technique reduces radiation exposure compared with radiographs but has limitations tied to image interpretation and device/operator factors.

There is an evidence gap concerning the value of screening with VFA in patients who do not have densitometry: the policy specifically addresses VFA without bone density study and finds insufficient evidence to support that screening with VFA alone improves health outcomes in patients not already eligible for treatment.

Diagnostic accuracy studies show variable results, with recent studies suggesting overall higher agreement of VFA with standard radiographs than older studies; VFA can identify patients without osteoporosis who might meet treatment recommendations. However, there is limited direct evidence from screening trials that adding VFA (with or without densitometry) to practice improves patient health outcomes, and no published treatment outcome data specifically for patients identified solely by VFA screening.

Definitions

VFAVertebral Fracture Assessment — imaging of the lateral spine performed with DXA densitometry software to detect vertebral fractures.

DXA/DEXADual-energy X-ray absorptiometry — bone mineral density testing method often combined with VFA.